Equities analysts expect Walgreens Boots Alliance, Inc. (NASDAQ:WBA) to report sales of $29.93 billion for the current quarter, Zacks reports. Seven analysts have made estimates for Walgreens Boots Alliance’s earnings, with estimates ranging from $28.01 billion to $30.66 billion. Walgreens Boots Alliance posted sales of $28.64 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 4.5%. The firm is scheduled to issue its next quarterly earnings results on Thursday, October 19th.

On average, analysts expect that Walgreens Boots Alliance will report full-year sales of $29.93 billion for the current fiscal year, with estimates ranging from $115.14 billion to $118.78 billion. For the next fiscal year, analysts forecast that the company will post sales of $127.65 billion per share, with estimates ranging from $120.46 billion to $133.53 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Walgreens Boots Alliance.

Walgreens Boots Alliance (NASDAQ:WBA) last announced its earnings results on Thursday, June 29th. The pharmacy operator reported $1.33 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.03. The firm had revenue of $30.12 billion for the quarter, compared to the consensus estimate of $29.72 billion. Walgreens Boots Alliance had a return on equity of 17.34% and a net margin of 3.69%. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.18 EPS.

Several brokerages recently commented on WBA. Needham & Company LLC began coverage on Walgreens Boots Alliance in a research note on Tuesday, June 27th. They set a “hold” rating on the stock. BidaskClub downgraded Walgreens Boots Alliance from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 24th. Leerink Swann set a $86.00 price target on Walgreens Boots Alliance and gave the company a “buy” rating in a research note on Friday, July 7th. Credit Suisse Group reissued a “buy” rating and issued a $97.00 price target on shares of Walgreens Boots Alliance in a research note on Thursday, July 13th. Finally, Pivotal Research set a $85.00 price target on Walgreens Boots Alliance and gave the company a “hold” rating in a research note on Sunday, July 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $90.88.

Shares of Walgreens Boots Alliance (WBA) traded down 0.34% during mid-day trading on Monday, reaching $81.50. The company’s stock had a trading volume of 5,024,951 shares. Walgreens Boots Alliance has a 12 month low of $75.18 and a 12 month high of $88.00. The firm has a market capitalization of $87.21 billion, a P/E ratio of 20.58 and a beta of 1.25. The company has a 50 day moving average of $79.95 and a 200-day moving average of $82.28.

Walgreens Boots Alliance declared that its board has approved a share repurchase program on Thursday, June 29th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the pharmacy operator to reacquire up to 5.9% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Friday, August 18th will be issued a $0.40 dividend. This is a boost from Walgreens Boots Alliance’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $1.60 annualized dividend and a dividend yield of 1.96%. Walgreens Boots Alliance’s dividend payout ratio (DPR) is presently 40.30%.

In related news, Director William C. Foote sold 2,736 shares of Walgreens Boots Alliance stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $79.79, for a total transaction of $218,305.44. Following the completion of the transaction, the director now owns 19,151 shares in the company, valued at $1,528,058.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 13.50% of the company’s stock.

A number of institutional investors have recently bought and sold shares of WBA. Intl Fcstone Inc. acquired a new position in Walgreens Boots Alliance during the second quarter worth approximately $1,156,000. M Holdings Securities Inc. acquired a new position in Walgreens Boots Alliance during the second quarter worth approximately $219,000. Griffin Asset Management Inc. acquired a new position in Walgreens Boots Alliance during the second quarter worth approximately $6,730,000. Achmea Investment Management B.V. boosted its position in Walgreens Boots Alliance by 22.1% in the second quarter. Achmea Investment Management B.V. now owns 50,907 shares of the pharmacy operator’s stock worth $3,985,000 after buying an additional 9,213 shares during the last quarter. Finally, Lord Abbett & CO. LLC boosted its position in Walgreens Boots Alliance by 7.2% in the second quarter. Lord Abbett & CO. LLC now owns 1,628,224 shares of the pharmacy operator’s stock worth $127,506,000 after buying an additional 108,919 shares during the last quarter. Institutional investors and hedge funds own 60.17% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/31/29-93-billion-in-sales-expected-for-walgreens-boots-alliance-inc-wba-this-quarter.html.

Walgreens Boots Alliance Company Profile

Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. The Company is a global pharmacy-led, health and wellbeing enterprise. Walgreens Boots Alliance operates through three divisions, including Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company’s products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand).

Get a free copy of the Zacks research report on Walgreens Boots Alliance (WBA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Walgreens Boots Alliance Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance Inc. and related stocks with our FREE daily email newsletter.